EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gallbladder cancer: current and future treatment options

Yanzhao Zhou, Kun Yuan, Yi Yang, Zemin Ji, Dezheng Zhou, Jingzhong Ouyang, Zhengzheng Wang, Fuqiang Wang, Chang Liu, Qingjun Li, Qi Zhang, Qiang Li und 2 weitere

Frontiers in Pharmacology · 11.05.2023 · 14

DOI: 10.3389/fphar.2023.1183619 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.05.2023. Verfasst von Yanzhao Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.

Schlagwörter

Stichwörter der Autor:innen

adjuvant therapyclinical stagegallbladder cancerimmunotherapytargeted therapy

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Department of Hepatobiliary Cancer, Liver Cancer Research Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Med…
  • Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Zitieren

APA

Zhou, Y., Yuan, K., Yang, Y., Ji, Z., Zhou, D., Ouyang, J., Wang, Z., Wang, F., Liu, C., Li, Q., Zhang, Q., Li, Q., Shan, X., & Zhou, J. (2023). Gallbladder cancer: current and future treatment options. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1183619

Vancouver

Zhou Y, Yuan K, Yang Y, Ji Z, Zhou D, Ouyang J, et al. Gallbladder cancer: current and future treatment options. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1183619

BibTeX
@article{Zhou2023,
  author = {Zhou, Yanzhao and Yuan, Kun and Yang, Yi and Ji, Zemin and Zhou, Dezheng and Ouyang, Jingzhong and Wang, Zhengzheng and Wang, Fuqiang and Liu, Chang and Li, Qingjun and Zhang, Qi and Li, Qiang and Shan, Xiao and Zhou, Jinxue},
  title = {Gallbladder cancer: current and future treatment options},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1183619}
}
Kostenlos starten →